VRTX241213C520000
- 0.13
- -0.62-82.67%
Vertex Pharmaceuticals Newsroom
TD Cowen Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $525
TD Cowen Keeps Their Buy Rating on Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals (VRTX) Falls More Steeply Than Broader Market: What Investors Need to Know
10 Health Care Stocks With Whale Alerts In Today's Session
Jefferies follows JPMorgan's call on Vertex Pharmaceuticals (VRTX.US) and raises the target price to $550.
Based on fundamentals and product pipeline, jefferies financial has upgraded vertex pharmaceuticals to buy.
Vertex Upgraded to Buy by Jefferies on Fundamentals, Pipeline
Vertex Has $5 Billion-Plus Opportunity In Pain And Kidney Disease Programs, Analyst Upgrades Stock
Vertex Reports Positive Long-term Data for Casgevy
A Glimpse Into The Expert Outlook On Vertex Pharmaceuticals Through 19 Analysts
Vertex Pharmaceuticals Raised to Buy From Hold by Jefferies
Vertex Pharmaceuticals Analyst Ratings
Jefferies Upgrades Vertex Pharmaceuticals(VRTX.US) to Buy Rating, Raises Target Price to $550
Express News | Vertex Pharmaceuticals Inc : Jefferies Raises to Buy From Hold
Reported Sunday, Vertex Highlights Long-Term Benefits Of CASGEVY For Sickle Cell Disease And Beta Thalassemia At ASH 2024
Evercore ISI Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)
FDA-Approved Sickle Cell Therapies From Bluebird Bio And Vertex Join Medicaid Innovation Program
CMS Rolls Out New Payment Model for Vertex, Bluebird Gene Therapies
10 Health Care Stocks Whale Activity In Today's Session
Express News | CMS: Cell & Gene Therapy Access Model Launches in Jan 2025, States May Choose to Begin Participation Anytime Between Jan 2025 & Jan 2026
Express News | CMS: 2 Drug Manufacturers With FDA-Approved Gene Therapies for Sickle Cell Disease to Participate in Cell & Gene Therapy Access Model With CMS